Basic Rx (HMO), Value Rx (HMO), Choice Rx (HMO-POS) and (HMO)
In September 2010, the HMO Research Network (HMORN) received a 1-year administrative supplement to...
1
In September 2010, the HMO Research Network (HMORN) received a 1-year administrative supplement to initiate development of a collaborative population-based laboratory, or “Collaboratory”. This award stems from NIH’s interest in enhancing the nation’s capacity to perform larger and more efficient epidemiological studies, interventions and analyses that collectively enable rapid responses to important questions in healthcare. The supplement is geared toward understanding the HMORN’s organizational structure and capacity in three areas: governance and operations; overall research portfolio and potential gaps in capacity; and data resources. This poster presents preliminary snapshots from the overall research portfolio of the HMORN for 2008-2009. Between November 2010 and January 2011, Collaboratory teams across the 15 HMORN sites in the U.S. queried local databases for research projects active at any time between 2008 and 2009 on which: (a) they were the prime site, and (b) 1 or more HMORN sites was a subcontract This list of HMORN projects was supplemented with: (a) multi-site projects with no HMORN prime site (e.g., VSD, external PI) (b) sub-studies of the CERT and DEcIDE networks Various administrative data sources were used to gather details about each study identified, including: (a) project title (e) prime and participating sites (b) PI (f ) start and end dates (c) total award (g) study design (d) funding agency (h) type of data collected The HMO Research Network – 2008-2009 Portfolio Snapshots BACKGROUND METHODS WHO FUNDED HMORN ACTIVITIES 95% of the Network’s research funding came from federal sources. Non-federal sources include foundations and societies, pharmaceutical industry entities, and internal research funded by the health plans. HHS FUNDING – A CLOSER LOOK Funding from federal sources is shown below for 2008 and 2009 (approximate). Support for the HMORN’s largest consortia (cancer, cardiovascular health, vaccine safety, mental health, medication safety) is clearly evident – as well as the HMORN’s capacity for healthcare delivery research. HMORN PROJECT PARTICIPATION The total number of sites involved ranged from 2 to 15 per project. On average, 5 sites were involved, with a standard deviation of 3.2. Of the 119 HMORN studies reported, 45 (38%) included non-HMORN partners. A total of 42 different external partners were reported, most of which are University-based. LIMITATIONS Not all projects may have been captured and reported. A greater portion of Cancer Research Network (CRN) projects may be reported. When number of VSD sites was not known, 8 sites were assumed. ACKNOWLEDGEMENTS Special thanks to and Karin Johnson, PhD and Sarah McDonald of GHRI, the entire HMORN Collaboratory team, and the Cancer Research Network supplement U19 CA 079689 – S12. 2008 2009 NCI $10,401,215 $16,293,831 NHLBI $4,352,927 $6,927,412 AHRQ $2,822,627 $2,622,200 NIA $1,316,875 $996,683 NIMH $1,095,266 $1,127,581 CDC $1,088,348 $2,858,724 FDA $907,565 $2,800,984 NCCAM $777,020 $63,865 NIH $591,355 $0 NIDDK $109,357 $235,744 NIAID $66,354 $66,354 N LM $0 $704,420 HMORN PROJECT LEADERSHIP Fifty-two different researchers from within the HMORN led or PI’ed a Network-based project during 2008 - 2009. External partners led or PI’ed 15 HMORN projects (13%) during the same period. HM O RN ProjectFunding,2008-2009 95% 2% 2% 1% Federal Foundation/N onprofit Pharm a Internal Projects led,by H M O RN Investigator 7 to 12 3 2 1 0 10 20 30 40 50 N um ber of projects led N um ber ofInvestigators H ow m any H M O RN sites per project? 2 3 to 5 6 to 9 10 to 15 0 10 20 30 40 50 60 N um ber ofprojects # Projects led,by H M O RN site 29 20 16 10 4 4 3 2 2 2 1 1 1 GHRI KPN KPNC HPHC HPRF KPHI MPCI KPGA MCRF KPSC KPCO LCF GHS N um ber of projects PROJECT TYPE The primary study design was reported for 110 of the projects. Of these, 62% primarily utilized observational methods. W hat study designs w ere m ost com m on? 68 6 2 10 2 7 5 10 O bservational P ilot/M odeling R egistry /S urveillance Infrastructure C luster R C T Random ized Trial P ractice-based Intervention /Evaluation Q ualitative or M ixed M ethod Num ber of projects LEAD SITES The number of projects led per HMORN site ranged from 0 to 29. Of the 15 U.S. sites, 13 led an HMORN project during 2008 and 2009.
-
Upload
austen-gallagher -
Category
Documents
-
view
214 -
download
1
Transcript of In September 2010, the HMO Research Network (HMORN) received a 1-year administrative supplement to...
In September 2010, the HMO Research Network (HMORN) received a 1-year administrative supplement to initiate development of a collaborative population-based laboratory, or “Collaboratory”. This award stems from NIH’s interest in enhancing the nation’s capacity to perform larger and more efficient epidemiological studies, interventions and analyses that collectively enable rapid responses to important questions in healthcare.
The supplement is geared toward understanding the HMORN’s organizational structure and capacity in three areas: governance and operations; overall research portfolio and potential gaps in capacity; and data resources.
This poster presents preliminary snapshots from the overall research portfolio of the HMORN for 2008-2009.
Between November 2010 and January 2011, Collaboratory teams across the 15 HMORN sites in the U.S. queried local databases for research projects active at any time between 2008 and 2009 on which:
(a) they were the prime site, and (b) 1 or more HMORN sites was a subcontract
This list of HMORN projects was supplemented with:
(a) multi-site projects with no HMORN prime site (e.g., VSD, external PI) (b) sub-studies of the CERT and DEcIDE networks
Various administrative data sources were used to gather details about each study identified, including:
(a) project title (e) prime and participating sites
(b) PI (f ) start and end dates (c) total award (g) study design (d) funding agency (h) type of data collected
Flags were added to projects linked to HMORN consortia (e.g., CRN, CVRN, etc.), and those funded through ARRA mechanisms.
The HMO Research Network – 2008-2009 Portfolio Snapshots
BACKGROUNDBACKGROUND
METHODSMETHODS
WHO FUNDED HMORN ACTIVITIES95% of the Network’s research funding came from federal sources. Non-federal sources include foundations and societies, pharmaceutical industry entities, and internal research funded by the health plans.
HHS FUNDING – A CLOSER LOOKFunding from federal sources is shown below for 2008 and 2009 (approximate). Support for the HMORN’s largest consortia (cancer, cardiovascular health, vaccine safety, mental health, medication safety) is clearly evident – as well as the HMORN’s capacity for healthcare delivery research.
HMORN PROJECT PARTICIPATIONThe total number of sites involved ranged from 2 to 15 per project. On average, 5 sites were involved, with a standard deviation of 3.2. Of the 119 HMORN studies reported, 45 (38%) included non-HMORN partners. A total of 42 different external partners were reported, most of which are University-based.
LIMITATIONS Not all projects may have been captured and reported. A greater portion of Cancer Research Network (CRN) projects may be reported. When number of VSD sites was not known, 8 sites were assumed.
ACKNOWLEDGEMENTS Special thanks to and Karin Johnson, PhD and Sarah McDonald of GHRI, the entire HMORN Collaboratory team, and the Cancer Research Network supplement U19 CA 079689 – S12.
2008 2009 NCI $10,401,215 $16,293,831 NHLBI $4,352,927 $6,927,412 AHRQ $2,822,627 $2,622,200 NIA $1,316,875 $996,683 NIMH $1,095,266 $1,127,581 CDC $1,088,348 $2,858,724 FDA $907,565 $2,800,984 NCCAM $777,020 $63,865 NIH $591,355 $0 NIDDK $109,357 $235,744 NIAID $66,354 $66,354 NLM $0 $704,420
HMORN PROJECT LEADERSHIPFifty-two different researchers from within the HMORN led or PI’ed a Network-based project during 2008 - 2009.
External partners led or PI’ed 15 HMORN projects (13%) during the same period.
HMORN Project Funding, 2008-2009
95%
2%
2%
1%
Federal Foundation/ Nonprofit Pharma Internal
Projects led, by HMORN Investigator
7 to 1232
1
0
10
20
30
40
50
Number of projects led
Num
ber
of In
vest
igato
rs
How many HMORN sites per project?
2
3 to 56 to 9
10 to 15
0
10
20
30
40
50
60
Num
ber
of pro
ject
s
# Projects led, by HMORN site
2920
1610
44
3222
111
GHRIKPN
KPNCHPHCHPRFKPHIMPCI
KPGAMCRFKPSCKPCO
LCFGHS
Number of projects
PROJECT TYPEThe primary study design was reported for 110 of the projects. Of these, 62% primarily utilized observational methods.
What study designs were most common?
68
6
2
10
2
7
5
10
Observational
Pilot / Modeling
Registry / Surveillance
Infrastructure
Cluster RCT
Randomized Trial
Practice-based Intervention / Evaluation
Qualitative or Mixed Method
Number of projects
LEAD SITESThe number of projects led per HMORN site ranged from 0 to 29. Of the 15 U.S. sites, 13 led an HMORN project during 2008 and 2009.
